

해외 바이오의약품 임상 현황 (2020.05.11~2020.05.17)

한국바이오의약품협회, 2020.5.19.
출처: ClinicalTrials.gov

○ 미국 12건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03735589	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IVD Fallopian Tube Cancer AJCC v8 Stage IVD Ovarian Cancer AJCC v8 Stage IVD Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04362189	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19	COVID-19	Drug: HB-adMSC Drug: Placebo Drug: HC Drug: AZ	Hope Biosciences Advanced Diagnostics Healthcare Hope Biosciences Stem Cell Research Foundation	Phase 2
NCT04354831	A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection	COVID-19	Biological: anti-SARS-CoV-2 convalescent plasma	Medical College of Wisconsin Froedtert Hospital	Phase 2
NCT04343976	Pegylated Interferon Lambda Treatment for COVID-19	COVID-19 COVID	Drug: Pegylated interferon lambda	Raymond Chung Eiger BioPharmaceuticals Massachusetts General Hospital	Phase 2
NCT04323956	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Ann Arbor Stage II Diffuse Large B-Cell Lymphoma Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage II Marginal Zone Lymphoma Ann Arbor Stage III Diffuse Large B-Cell Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage III Marginal Zone Lymphoma Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma Ann Arbor Stage IV Follicular Lymphoma Ann Arbor Stage IV Marginal Zone Lymphoma Diffuse Large B-Cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Indolent Non-Hodgkin Lymphoma	Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Drug: Parsaclisib Biological: Pegfilgrastim Drug: Prednisone Biological: Rituximab Drug: Vincristine Sulfate	Mayo Clinic National Cancer Institute (NCI)	Phase 1
NCT04237623	GM-CSF With Post-Transplant Cyclophosphamide	Transplant-Related Hematologic Malignancy	Drug: Sargramostim Other: Control Arm	Northside Hospital, Inc.	Phase 2
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Aggressive Non-Hodgkin Lymphoma ALK-Positive Large B-Cell Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Biological: Rituximab Drug: Prednisone Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Biological: Filgrastim	University of Washington National Cancer Institute (NCI) Genentech, Inc.	Phase 1
NCT04230031	Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab	Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health	Phase 2
NCT04165083	Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYNOTE-01B)	Carcinoma, Non-Small-Cell Lung	Biological: Pembrolizumab Biological: MK-4830	Merck Sharp & Dohme Corp.	Phase 2
NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	Locally Advanced Malignant Solid Neoplasm Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8 Unresectable Malignant Solid Neoplasm	Biological: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 Drug: VLP-encapsulated TLR9 Agonist CMP-001	University of Southern California National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04152863	Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)	Advanced/Metastatic Melanoma	Biological: V937 IV Biological: V937 IT Drug: Pembrolizumab	Merck Sharp & Dohme Corp.	Phase 2
NCT04285567	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine	Hoffmann-La Roche	Phase 3

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04379076	Interleukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection UK Cohort	COVID-19 Lymphocytopenia	Drug: Interleukin-7 Drug: Placebos	Revimmune Amarex Clinical Research	Phase 2

해외 바이오의약품 임상 현황 (2020.05.11~2020.05.17)

한국바이오의약품협회, 2020.5.19.
출처: ClinicalTrials.gov

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04384549	Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers	Infection Viral, Agent as Cause of Disease Classified Elsewhere	Biological: BCG GROUP Other: PLACEBO GROUP	Assistance Publique - H c̐pitaux de Paris	Phase 3
NCT04285567	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax Drug: Fludarabine Drug: Cyclophosphamide Drug: Rituximab Drug: Bendamustine	Hoffmann-La Roche	Phase 3

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04335890	IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma	Melanoma, Uveal Metastatic	Biological: Vaccination with IKKb matured Dendritic Cells	Hasumi International Research Foundation	Phase 1

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04389177	Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC	Esophageal Squamous Cell Carcinoma Stage III	Drug: Pembrolizumab Injection [Keytruda]	Tianjin Medical University Cancer Institute and Hospital	Phase 2
NCT04386707	Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine	Poliomyelitis	Biological: Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age Biological: Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age Biological: Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age Biological: Three doses control wIPV at the schedule of 2,3,4 months of age	Sinovac Biotech Co., Ltd	Phase 3

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04368429	Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age	Meningococcal Infection (Healthy Volunteers)	Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine	Sanofi	Phase 3